[ad_1]
National Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 48.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 19,990 shares of the biopharmaceutical company’s stock after selling 19,112 shares during the quarter. National Asset Management Inc.’s holdings in Gilead Sciences were worth $1,189,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Gilbert & Cook Inc. boosted its stake in Gilead Sciences by 5.8% in the first quarter. Gilbert & Cook Inc. now owns 5,178 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 284 shares during the last quarter. Hall Private Wealth Advisors boosted its stake in Gilead Sciences by 13.1% in the first quarter. Hall Private Wealth Advisors now owns 144,162 shares of the biopharmaceutical company’s stock valued at $8,570,000 after acquiring an additional 16,684 shares during the last quarter. LeJeune Puetz Investment Counsel LLC boosted its stake in Gilead Sciences by 1.7% in the first quarter. LeJeune Puetz Investment Counsel LLC now owns 28,295 shares of the biopharmaceutical company’s stock valued at $1,682,000 after acquiring an additional 475 shares during the last quarter. Roosevelt Investment Group LLC boosted its stake in Gilead Sciences by 22.6% in the first quarter. Roosevelt Investment Group LLC now owns 5,172 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 955 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc. bought a new position in Gilead Sciences in the first quarter valued at approximately $264,000. 80.16% of the stock is owned by institutional investors.
Gilead Sciences Trading Down 0.3 %
Shares of NASDAQ:GILD opened at $60.80 on Monday. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $74.12. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The company’s fifty day simple moving average is $62.18 and its 200 day simple moving average is $62.57. The firm has a market cap of $76.26 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 0.61 and a beta of 0.38.
Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same period in the previous year, the business earned $2.08 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.59 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th were paid a $0.73 dividend. The ex-dividend date of this dividend was Tuesday, June 14th. This represents a $2.92 annualized dividend and a yield of 4.80%. Gilead Sciences’s payout ratio is currently 81.56%.
Analyst Ratings Changes
A number of equities analysts have issued reports on GILD shares. SVB Leerink started coverage on shares of Gilead Sciences in a research note on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price objective on the stock. Piper Sandler cut their target price on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating on the stock in a report on Monday, May 16th. Morgan Stanley increased their target price on shares of Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a report on Tuesday, April 12th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $72.07.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
Featured Articles
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).
Receive News & Ratings for Gilead Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link